🇩🇪 🇩🇪 🔥 Voyager Acquisition Aktie: Veraxa springt mit Millionen-Paket ein - AD HOC NEWS
👉 Hier tippen für den ganzen Artikel 👇
#Voyager #Acquisition #Aktie #Veraxa
👉 Hier tippen für den ganzen Artikel 👇
#Voyager #Acquisition #Aktie #Veraxa
Voyager Acquisition Aktie: Veraxa springt mit Millionen-Paket ein - AD HOC NEWS
news.google.com
May 31, 2026 at 10:14 AM
🇩🇪 🇩🇪 🔥 Voyager Acquisition Aktie: Veraxa springt mit Millionen-Paket ein - AD HOC NEWS
👉 Hier tippen für den ganzen Artikel 👇
#Voyager #Acquisition #Aktie #Veraxa
👉 Hier tippen für den ganzen Artikel 👇
#Voyager #Acquisition #Aktie #Veraxa
POLAND: AI-enabled drug discovery collaboration with VERAXA biotech to support growing BiTAC® pipeline
rcnworldwidemedia.blogspot.com/2026/07/pola...
rcnworldwidemedia.blogspot.com/2026/07/pola...
POLAND: AI-enabled drug discovery collaboration with VERAXA biotech to support growing BiTAC® pipeline
rcnworldwidemedia.blogspot.com
July 14, 2026 at 4:45 PM
POLAND: AI-enabled drug discovery collaboration with VERAXA biotech to support growing BiTAC® pipeline
rcnworldwidemedia.blogspot.com/2026/07/pola...
rcnworldwidemedia.blogspot.com/2026/07/pola...
🎉 #VERAXA Biotech begins trading today on NASDAQ (#$VRXA)!
As a public company, we’re pioneering cancer therapies via our BiTAC platform—dual-antigen, conditionally activated targeting designed to attack cancer cells while sparing healthy tissue.
Read more: bit.ly/4ooC21e
As a public company, we’re pioneering cancer therapies via our BiTAC platform—dual-antigen, conditionally activated targeting designed to attack cancer cells while sparing healthy tissue.
Read more: bit.ly/4ooC21e
June 11, 2026 at 1:30 PM
🎉 #VERAXA Biotech begins trading today on NASDAQ (#$VRXA)!
As a public company, we’re pioneering cancer therapies via our BiTAC platform—dual-antigen, conditionally activated targeting designed to attack cancer cells while sparing healthy tissue.
Read more: bit.ly/4ooC21e
As a public company, we’re pioneering cancer therapies via our BiTAC platform—dual-antigen, conditionally activated targeting designed to attack cancer cells while sparing healthy tissue.
Read more: bit.ly/4ooC21e
Today is World Lung Cancer Day, and we at Veraxa Biotech stand with the millions of patients around the world fighting for better treatment options.
#WorldLungCancerDay2026 #TogetherThroughLungCancer #LungCancerResearch
#WorldLungCancerDay2026 #TogetherThroughLungCancer #LungCancerResearch
August 1, 2026 at 12:13 PM
Today is World Lung Cancer Day, and we at Veraxa Biotech stand with the millions of patients around the world fighting for better treatment options.
#WorldLungCancerDay2026 #TogetherThroughLungCancer #LungCancerResearch
#WorldLungCancerDay2026 #TogetherThroughLungCancer #LungCancerResearch
Congratulations to VERAXA Biotech GmbH, a Swiss biopharmaceutical company co-founded by members of the Lemke Lab team. They plan to to enter the stock market and go public through a merger with Voyager Acquisition Corp., a U.S.-based SPAC! You can read more here: lemkelab.com/company-co-f...
Company co-founded by Lemke Lab team members plans to enter stock market
The press release announces that VERAXA Biotech AG, a Swiss biopharmaceutical company co-founded by members of the Lemke Lab team, plans to go public through a […]
lemkelab.com
May 16, 2025 at 8:00 AM
Congratulations to VERAXA Biotech GmbH, a Swiss biopharmaceutical company co-founded by members of the Lemke Lab team. They plan to to enter the stock market and go public through a merger with Voyager Acquisition Corp., a U.S.-based SPAC! You can read more here: lemkelab.com/company-co-f...
VERAXA Biotech (NASDAQ: VRXA) partners with Ardigen to bring AI-driven tools to its BiTAC cancer drug platform, aiming to improve tumor targeting and reduce toxicity by analyzing large clinical datasets. A key step forward in precision oncology. #Oncology #Biotech
July 13, 2026 at 5:04 PM
VERAXA Biotech (NASDAQ: VRXA) partners with Ardigen to bring AI-driven tools to its BiTAC cancer drug platform, aiming to improve tumor targeting and reduce toxicity by analyzing large clinical datasets. A key step forward in precision oncology. #Oncology #Biotech
🤝 Join #VERAXA Biotech at BIO International, San Diego, June 22-25!
Katharina Billian-Frey, Director of Business Development, is looking forward to discussing our BiTAC platform and how we’re changing cancer therapy with AND-gated strategies.
Schedule via BIO One-on-One!
Katharina Billian-Frey, Director of Business Development, is looking forward to discussing our BiTAC platform and how we’re changing cancer therapy with AND-gated strategies.
Schedule via BIO One-on-One!
June 15, 2026 at 1:03 PM
🤝 Join #VERAXA Biotech at BIO International, San Diego, June 22-25!
Katharina Billian-Frey, Director of Business Development, is looking forward to discussing our BiTAC platform and how we’re changing cancer therapy with AND-gated strategies.
Schedule via BIO One-on-One!
Katharina Billian-Frey, Director of Business Development, is looking forward to discussing our BiTAC platform and how we’re changing cancer therapy with AND-gated strategies.
Schedule via BIO One-on-One!
📈 VRXA (Veraxa Biotech Holding AG) +11.1% since we peeled back the filing
Filed: Jul 7, 2026 | 12:07 ET | Now: Jul 7, 2026 | 17:18 ET
At filing: $2.70 to Now: $3.00
Score: 7/10 | Positive
Headlines are late. Filings aren't.
Read the original breakdown (sourced from Wiseek):
Filed: Jul 7, 2026 | 12:07 ET | Now: Jul 7, 2026 | 17:18 ET
At filing: $2.70 to Now: $3.00
Score: 7/10 | Positive
Headlines are late. Filings aren't.
Read the original breakdown (sourced from Wiseek):
July 7, 2026 at 9:19 PM
📈 VRXA (Veraxa Biotech Holding AG) +11.1% since we peeled back the filing
Filed: Jul 7, 2026 | 12:07 ET | Now: Jul 7, 2026 | 17:18 ET
At filing: $2.70 to Now: $3.00
Score: 7/10 | Positive
Headlines are late. Filings aren't.
Read the original breakdown (sourced from Wiseek):
Filed: Jul 7, 2026 | 12:07 ET | Now: Jul 7, 2026 | 17:18 ET
At filing: $2.70 to Now: $3.00
Score: 7/10 | Positive
Headlines are late. Filings aren't.
Read the original breakdown (sourced from Wiseek):
VERAXA Biotech (NASDAQ: VRXA) appoints Dr. Christoph Erkel as CSO to advance its proprietary BiTAC T cell engager platform toward clinical development. Preclinical data at AACR showed promising selective cancer cell activity. #Oncology #Biotech
September 10, 2026 at 8:00 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Dr. Christoph Erkel as CSO to advance its proprietary BiTAC T cell engager platform toward clinical development. Preclinical data at AACR showed promising selective cancer cell activity. #Oncology #Biotech
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global finance expertise to accelerate its next-gen cancer therapy pipeline and proprietary BiTAC platform. #Biotech #Oncology
September 8, 2026 at 8:01 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global finance expertise to accelerate its next-gen cancer therapy pipeline and proprietary BiTAC platform. #Biotech #Oncology
#VRXA VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
https://www.stocktitan.net/news/VRXA/veraxa-biotech-appoints-raju-willener-as-chief-financial-sq9w6gd5y206.html
https://www.stocktitan.net/news/VRXA/veraxa-biotech-appoints-raju-willener-as-chief-financial-sq9w6gd5y206.html
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 4, 2026 at 11:00 AM
#VRXA VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
https://www.stocktitan.net/news/VRXA/veraxa-biotech-appoints-raju-willener-as-chief-financial-sq9w6gd5y206.html
https://www.stocktitan.net/news/VRXA/veraxa-biotech-appoints-raju-willener-as-chief-financial-sq9w6gd5y206.html
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global finance experience to support its capital strategy and BiTAC cancer therapy platform. #Biotech #Oncology
September 4, 2026 at 8:03 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global finance experience to support its capital strategy and BiTAC cancer therapy platform. #Biotech #Oncology
VERAXA Biotech (NASDAQ: VRXA) advances its VXA-222 cancer program beyond discovery, filing first patents on its BiTAC platforms while building a diversified oncology pipeline of bispecific antibodies and ADCs. #Oncology #Biotech
August 27, 2026 at 11:13 AM
VERAXA Biotech (NASDAQ: VRXA) advances its VXA-222 cancer program beyond discovery, filing first patents on its BiTAC platforms while building a diversified oncology pipeline of bispecific antibodies and ADCs. #Oncology #Biotech
VERAXA Biotech (NASDAQ: VRXA) and Secarna report early positive results from their AOC collaboration, showing greater potency than unconjugated oligonucleotides in autoimmune disease research. A promising step for next-gen therapeutics. #Biotech #Immunology
August 27, 2026 at 11:12 AM
VERAXA Biotech (NASDAQ: VRXA) and Secarna report early positive results from their AOC collaboration, showing greater potency than unconjugated oligonucleotides in autoimmune disease research. A promising step for next-gen therapeutics. #Biotech #Immunology
VERAXA Biotech (NASDAQ: VRXA) receives favorable regulatory guidance from Germany's Paul-Ehrlich-Institute for its lead BiTAC-TCE cancer therapy, potentially clearing the path toward clinical trials. Preclinical data showed selective dual-biomarker cancer cell targeting. #Oncology #Biotech
August 27, 2026 at 11:13 AM
VERAXA Biotech (NASDAQ: VRXA) receives favorable regulatory guidance from Germany's Paul-Ehrlich-Institute for its lead BiTAC-TCE cancer therapy, potentially clearing the path toward clinical trials. Preclinical data showed selective dual-biomarker cancer cell targeting. #Oncology #Biotech
VERAXA Biotech (NASDAQ: VRXA) advances its dual-targeting BiTAC cancer platform, with its lead T-cell engager nearing IND-enabling studies and VXA-222 bispecific ADC moving past discovery. 50+ patents support a growing oncology pipeline. #Oncology #Biotech
August 27, 2026 at 11:18 AM
VERAXA Biotech (NASDAQ: VRXA) advances its dual-targeting BiTAC cancer platform, with its lead T-cell engager nearing IND-enabling studies and VXA-222 bispecific ADC moving past discovery. 50+ patents support a growing oncology pipeline. #Oncology #Biotech
#VRXA VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
https://www.stocktitan.net/news/VRXA/veraxa-biotech-and-secarna-pharmaceuticals-achieve-research-eiagkzz0ndp6.html
https://www.stocktitan.net/news/VRXA/veraxa-biotech-and-secarna-pharmaceuticals-achieve-research-eiagkzz0ndp6.html
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
VERAXA Biotech (NASDAQ: VRXA) and Secarna Pharmaceuticals reported a research milestone in their alliance to develop antibody-oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases. In early in vitro proof-of-concept work, an AOC candidate created by combining both companies’ technologies showed higher potency than the equivalent unconjugated, “naked” oligonucleotide.According to VERAXA, this demonstrates that its click-chemistry-based conjugation platform can be efficiently applied beyond its core focus in solid tumors. Both parties are now discussing next steps to further advance this AOC collaboration.
www.stocktitan.net
August 24, 2026 at 11:00 AM
#VRXA VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
https://www.stocktitan.net/news/VRXA/veraxa-biotech-and-secarna-pharmaceuticals-achieve-research-eiagkzz0ndp6.html
https://www.stocktitan.net/news/VRXA/veraxa-biotech-and-secarna-pharmaceuticals-achieve-research-eiagkzz0ndp6.html
VERAXA Biotech (NASDAQ: VRXA) teams up with Ardigen to apply AI to its oncology pipeline, targeting smarter drug combinations and reducing development risks through advanced computational biology. #Oncology #Biotech
August 18, 2026 at 8:01 PM
VERAXA Biotech (NASDAQ: VRXA) teams up with Ardigen to apply AI to its oncology pipeline, targeting smarter drug combinations and reducing development risks through advanced computational biology. #Oncology #Biotech
VERAXA Biotech (NASDAQ: VRXA) partners with Ardigen to use AI in advancing its precision oncology pipeline, targeting dual-cancer markers to improve therapy safety and reduce development risk. #Oncology #Biotech
August 18, 2026 at 8:02 PM
VERAXA Biotech (NASDAQ: VRXA) partners with Ardigen to use AI in advancing its precision oncology pipeline, targeting dual-cancer markers to improve therapy safety and reduce development risk. #Oncology #Biotech
VERAXA Biotech (NASDAQ: VRXA) is advancing its BiTAC platform in antibody-drug conjugates and T-cell engagers, two areas drawing massive pharma investment. Its pipeline targets future partnerships, licensing deals, and asset transactions. #Biotech #AntibodyTherapeutics
August 7, 2026 at 8:01 PM
VERAXA Biotech (NASDAQ: VRXA) is advancing its BiTAC platform in antibody-drug conjugates and T-cell engagers, two areas drawing massive pharma investment. Its pipeline targets future partnerships, licensing deals, and asset transactions. #Biotech #AntibodyTherapeutics
VERAXA Biotech (NASDAQ: VRXA) advances its VXA-222 bispecific antibody-drug conjugate beyond discovery phase while expanding its patent portfolio to 50+ granted patents with protection extending to 2047. A major step forward in next-gen cancer therapy. #Oncology #Biotech
August 6, 2026 at 8:00 PM
VERAXA Biotech (NASDAQ: VRXA) advances its VXA-222 bispecific antibody-drug conjugate beyond discovery phase while expanding its patent portfolio to 50+ granted patents with protection extending to 2047. A major step forward in next-gen cancer therapy. #Oncology #Biotech